Dr. Cheryl J. Barnes
Dermatology (Dermatology Physician)
119 W Hill St
Thomasville, GA 31792
Who else practices at this address →
Thomas County is a federal mental health shortage area. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of South Carolina School of Medicine (1996)
- Years since graduation
- 30
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 1,017
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1996Medical school: University of South Carolina School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Dermatology Physician primary
GA license 044161
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Privia Medical Group of Georgia LLC (462 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,017
- Services billed
- 6,360
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Destruction of precancer skin growth, 2-14 growths | 1,860 | 294 |
| Established patient office or other outpatient visit, 20-29 minutes | 1,330 | 917 |
| Biopsy of related skin growth, first growth | 525 | 434 |
| Destruction of precancer skin growth, 1 growth | 518 | 391 |
| Biopsy of related skin growth, each additional growth | 381 | 199 |
| Destruction of skin growth, 1-14 growths | 369 | 315 |
| Established patient office or other outpatient visit, 30-39 minutes | 128 | 118 |
| New patient office or other outpatient visit, 30-44 minutes | 66 | 66 |
| Destruction of precancer skin growth, 15 or more growths | 53 | 45 |
| Destruction of cancer skin growth of trunk, arms, or legs, 0.6-1.0 cm | 48 | 43 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 21 companies reported 73 payments worth $1,604 in total to this clinician.
| AbbVie Inc. | $397 |
|---|---|
| Regeneron Healthcare Solutions, Inc. | $260 |
| Pfizer Inc. | $190 |
| Janssen Biotech, Inc. | $99.00 |
| Sanofi-aventis U.S. LLC | $85.00 |
| Lilly USA, LLC | $81.44 |
| Leo Pharma Inc. | $73.71 |
| Seqirus USA Inc | $58.34 |
| Food and Beverage | $1,413 |
|---|---|
| Education | $191 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Janssen Biotech, Inc. Apr 24, 2025 | Education TREMFYA · Immunology · in-kind | $99.00 |
| Sanofi-aventis U.S. LLC Sep 10, 2025 | Education DUPIXENT · Immunology · in-kind | $85.00 |
| Regeneron Healthcare Solutions, Inc. Mar 19, 2025 | Education DUPIXENT · IMMUNOLOGY AND INFLAMMATION · in-kind | $6.77 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $30,436 in research payments for these studies, mostly to the institutions running them.
- A Phase 3, Randomized, 52-week, Placebo-controlled, Double-blind Study With Re-randomization to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab (AMG 451) in Adolescent Subjects With Moderate-to-severe At…
Amgen Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.